• L van der Heijden, M A J van de Sande, I C M van der Geest, H W B Schreuder, B J van Royen, P C Jutte, J A M Bramer, F C Öner, A P van Noort-Suijdendorp, H M Kroon, and P D S Dijkstra.
• Department of Orthopedic Surgery, Leiden University Medical Center (LUMC), Postzone J11-70, PO Box 9600, 2300 RC, Leiden, The Netherlands, lvanderheijden@lumc.nl.
• Eur Spine J. 2014 Sep 1; 23 (9): 1949-62.

PurposeEvaluation of recurrences, complications and function at mid-term follow-up after curettage for sacral giant cell tumor (GCT).MethodsWe retrospectively studied all 26 patients treated for sacral GCT in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6-229) months. All patients underwent intralesional excision, 21 with local adjuvants, 5 radiotherapy, 3 IFN-α, 1 bisphosphonates. Functional outcome was assessed using Musculoskeletal Tumor Society (MSTS) score. Statistics were performed with Kaplan-Meier, Cox regression, log rank and Mann-Whitney U.ResultsRecurrence rate was 14/26 after median 13 (3-139) months and was highest after isolated curettage (4/5). Soft tissue masses >10 cm increased recurrence risk (HR = 3.3, 95 % CI = 0.81-13, p = 0.09). Complications were reported in 12/26 patients. MSTS was superior in patients without complications (27 vs. 21; p = 0.024).ConclusionRecurrence rate for sacral GCT was highest after isolated curettage, indicating that (local) adjuvant treatment is desired to obtain immediate local control. Complications were common and impaired function.

36 keywords...

hide…